{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:49:50Z","timestamp":1790178590721,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.ajkd.2013.10.011","type":"journal-article","created":{"date-parts":[[2013,12,15]],"date-time":"2013-12-15T11:46:39Z","timestamp":1387107999000},"page":"446-455","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease"],"prefix":"10.1053","volume":"63","clinical-trial-number":[{"clinical-trial-number":"nct01616927","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Esther","family":"Meijer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost P.H.","family":"Drenth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hedwig","family":"d'Agnolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niek F.","family":"Casteleijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan W.","family":"de Fijter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom J.","family":"Gevers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kappert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien J.M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahdi","family":"Salih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Soonawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin M.","family":"Spithoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Folkert W.","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack F.M.","family":"Wetzels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Zietse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron T.","family":"Gansevoort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1053\/j.ajkd.2013.10.011_bib1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"9147","key":"10.1053\/j.ajkd.2013.10.011_bib2","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0140-6736(98)03495-3","article-title":"Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group","volume":"353","author":"Hateboer","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib3","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ajkd.2007.10.037","article-title":"Variation in age at ESRD in autosomal dominant polycystic kidney disease","volume":"51","author":"Reed","year":"2008","journal-title":"Am J Kidney Dis"},{"issue":"1","key":"10.1053\/j.ajkd.2013.10.011_bib4","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","article-title":"Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease Cohort","volume":"1","author":"Bae","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib5","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrgastro.2012.254","article-title":"Diagnosis and management of polycystic liver disease","volume":"10","author":"Gevers","year":"2013","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib6","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.ackd.2010.01.006","article-title":"Treatment strategies and clinical trial design in ADPKD","volume":"17","author":"Torres","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2013.10.011_bib7","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1681\/ASN.2010030262","article-title":"Randomized intervention studies in human polycystic kidney and liver disease","volume":"21","author":"Schrier","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ajkd.2013.10.011_bib8","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","article-title":"Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease","volume":"68","author":"Ruggenenti","year":"2005","journal-title":"Kidney Int"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1053\/j.ajkd.2010.11.029","article-title":"Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study","volume":"57","author":"Torres","year":"2011","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2013.10.011_bib10","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1681\/ASN.2009040421","article-title":"Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1","volume":"21","author":"Shillingford","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"14","key":"10.1053\/j.ajkd.2013.10.011_bib11","doi-asserted-by":"crossref","first-page":"5466","DOI":"10.1073\/pnas.0509694103","article-title":"The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease","volume":"103","author":"Shillingford","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1053\/j.ajkd.2013.10.011_bib12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1681\/ASN.2004080660","article-title":"Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease","volume":"16","author":"Tao","year":"2005","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2013.10.011_bib13","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1056\/NEJMoa1003491","article-title":"Everolimus in patients with autosomal dominant polycystic kidney disease","volume":"363","author":"Walz","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1053\/j.ajkd.2013.10.011_bib14","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJMoa0907419","article-title":"Sirolimus and kidney growth in autosomal dominant polycystic kidney disease","volume":"363","author":"Serra","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"10.1053\/j.ajkd.2013.10.011_bib15","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.2215\/CJN.03530411","article-title":"Tolvaptan in autosomal dominant polycystic kidney disease: three years' experience","volume":"6","author":"Higashihara","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"issue":"25","key":"10.1053\/j.ajkd.2013.10.011_bib16","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1053\/j.ajkd.2013.10.011_bib17","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/ncpneph0070","article-title":"Mechanisms of disease: autosomal dominant and recessive polycystic kidney diseases","volume":"2","author":"Torres","year":"2006","journal-title":"Nat Clin Pract Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib18","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1053\/j.gastro.2009.07.052","article-title":"Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"van Keimpema","year":"2009","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1053\/j.ajkd.2013.10.011_bib19","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1681\/ASN.2009121291","article-title":"Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease","volume":"21","author":"Hogan","year":"2010","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.2215\/CJN.05380709","article-title":"Reducing polycystic liver volume in ADPKD: effects of somatostatin analogue octreotide","volume":"5","author":"Caroli","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"issue":"9","key":"10.1053\/j.ajkd.2013.10.011_bib21","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"issue":"9903","key":"10.1053\/j.ajkd.2013.10.011_bib22","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/S0140-6736(13)61407-5","article-title":"Effect of long-acting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial","volume":"382","author":"Caroli","year":"2013","journal-title":"Lancet"},{"issue":"1","key":"10.1053\/j.ajkd.2013.10.011_bib23","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1681\/ASN.2008050507","article-title":"Unified criteria for ultrasonographic diagnosis of ADPKD","volume":"20","author":"Pei","year":"2009","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1053\/j.ajkd.2013.10.011_bib24","first-page":"155A","article-title":"A simplified equation to predict glomerular filtration rate from serum creatinine [Abstract]","volume":"11","author":"Levey","year":"2000","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib25","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/S0009-9236(99)70011-1","article-title":"Pharmacokinetics of the somatostatin analog lanreotide in patients with severe chronic renal insufficiency","volume":"66","author":"Barbanoj","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib26","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1046\/j.1523-1755.2003.00776.x","article-title":"Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease","volume":"63","author":"Schrier","year":"2003","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib27","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1440-1797.2006.00535.x","article-title":"Optimal care of autosomal dominant polycystic kidney disease patients","volume":"11","author":"Schrier","year":"2006","journal-title":"Nephrology (Carlton)"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib28","first-page":"1282","article-title":"Postmenopausal estrogen therapy selectively stimulates hepatic enlargement in women with autosomal dominant polycystic kidney disease","volume":"26","author":"Sherstha","year":"1997","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib29","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1053\/j.ackd.2010.01.003","article-title":"Extrarenal manifestations of autosomal dominant polycystic kidney disease","volume":"17","author":"Pirson","year":"2010","journal-title":"Adv Chronic Kidney Dis"},{"issue":"9","key":"10.1053\/j.ajkd.2013.10.011_bib30","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1007\/s10620-006-9120-6","article-title":"Evaluation of a gastrointestinal symptoms questionnaire","volume":"51","author":"Bovenschen","year":"2006","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib31","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1515\/CCLM.2009.121","article-title":"Stability of selected serum proteins after long-term storage in the Janus serum bank","volume":"47","author":"Gislefoss","year":"2009","journal-title":"Clin Chem Lab Med"},{"issue":"15","key":"10.1053\/j.ajkd.2013.10.011_bib32","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1016\/j.clinbiochem.2013.06.022","article-title":"DIPAK Consortium Investigators. Stability of creatinine and cystatin C in whole blood","volume":"46","author":"Spithoven","year":"2013","journal-title":"Clin Biochem"},{"issue":"12","key":"10.1053\/j.ajkd.2013.10.011_bib33","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1681\/ASN.V5122037","article-title":"Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group","volume":"5","author":"Klahr","year":"1995","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2013.10.011_bib34","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/ng1293-359","article-title":"Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease","volume":"5","author":"Peters","year":"1993","journal-title":"Nat Genet"},{"issue":"5266","key":"10.1053\/j.ajkd.2013.10.011_bib35","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1126\/science.272.5266.1339","article-title":"PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein","volume":"272","author":"Mochizuki","year":"1996","journal-title":"Science"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0092-8674(95)90339-9","article-title":"Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. The International Polycystic Kidney Disease Consortium","volume":"81","author":"Anonymous","year":"1995","journal-title":"Cell"},{"issue":"4","key":"10.1053\/j.ajkd.2013.10.011_bib37","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1097\/01.mnh.0000232888.65895.e7","article-title":"Understanding pathogenic mechanisms in polycystic kidney disease provides clues for therapy","volume":"15","author":"Harris","year":"2006","journal-title":"Curr Opin Nephrol Hypertens"},{"issue":"3","key":"10.1053\/j.ajkd.2013.10.011_bib38","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/j.1523-1755.2004.00843.x","article-title":"Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cells","volume":"66","author":"Belibi","year":"2004","journal-title":"Kidney Int"},{"issue":"4","key":"10.1053\/j.ajkd.2013.10.011_bib39","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM199601253340408","article-title":"Octreotide","volume":"334","author":"Lamberts","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib40","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/ki.2009.128","article-title":"Autosomal dominant polycystic kidney disease: the last 3 years","volume":"76","author":"Torres","year":"2009","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib41","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","article-title":"Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking in\u00a0vitro","volume":"94","author":"Lesche","year":"2009","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1053\/j.ajkd.2013.10.011_bib42","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/PPA.S20783","article-title":"Lanreotide depot deep subcutaneous injection: a new method of delivery and its associated benefits","volume":"6","author":"Carmichael","year":"2012","journal-title":"Patient Prefer Adherence"},{"issue":"24","key":"10.1053\/j.ajkd.2013.10.011_bib43","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJM198312153092406","article-title":"Somatostatin","volume":"309","author":"Reichlin","year":"1983","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1053\/j.ajkd.2013.10.011_bib44","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1369\/jhc.2008.950998","article-title":"Expression of somatostatin and somatostatin receptor subtypes 1-5 in human normal and diseased kidney","volume":"56","author":"Bhandari","year":"2008","journal-title":"J\u00a0Histochem Cytochem"},{"issue":"3","key":"10.1053\/j.ajkd.2013.10.011_bib45","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","article-title":"Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3\u2032,5\u2032-cyclic monophosphate","volume":"132","author":"Masyuk","year":"2007","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1053\/j.ajkd.2013.10.011_bib46","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/hep.26140","article-title":"Pasireotide is more effective than octreotide in reducing hepato-renal cystogenesis in rodents with polycystic kidney and liver diseases","volume":"58","author":"Masyuk","year":"2012","journal-title":"Hepatology"},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib47","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1365-2036.2011.04923.x","article-title":"The long-term outcome of patients with polycystic liver disease treated with lanreotide","volume":"35","author":"Chrispijn","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"10.1053\/j.ajkd.2013.10.011_bib48","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1093\/ndt\/gfs152","article-title":"Somatostatin analog therapy for severe polycystic liver disease: results after 2 years","volume":"27","author":"Hogan","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ajkd.2013.10.011_bib49","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2369-13-17","article-title":"Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease","volume":"13","author":"Gevers","year":"2012","journal-title":"BMC Nephrol"},{"key":"10.1053\/j.ajkd.2013.10.011_bib50","unstructured":"Hogan M. Pasireotide LAR in severe polycystic liver disease. Study number: NCT 01670110. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01670110. Accessed August 17, 2012."},{"key":"10.1053\/j.ajkd.2013.10.011_bib51","unstructured":"Mario Negri Institute for Pharmacological Research. Somatostatin in patients with autosomal dominant polycystic kidney disease and moderate to severe renal insufficiency (ALADIN 2). Study number: NCT 01377246. http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01377246. Accessed June 20, 2011."},{"issue":"2","key":"10.1053\/j.ajkd.2013.10.011_bib52","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","article-title":"Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review","volume":"14","author":"Fleseriu","year":"2011","journal-title":"Pituitary"},{"issue":"3","key":"10.1053\/j.ajkd.2013.10.011_bib53","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/MOG.0b013e328343433f","article-title":"Somatostatin analogues for treatment of polycystic liver disease","volume":"27","author":"Gevers","year":"2011","journal-title":"Curr Opin Gastroenterol"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib54","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1053\/j.ajkd.2010.06.023","article-title":"Association of urinary biomarkers with disease severity in patients with autosomal dominant polycystic kidney disease: a cross-sectional analysis","volume":"56","author":"Meijer","year":"2010","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1053\/j.ajkd.2013.10.011_bib55","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.ajkd.2012.08.038","article-title":"Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort","volume":"61","author":"Boertien","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"8","key":"10.1053\/j.ajkd.2013.10.011_bib56","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1093\/ndt\/gfr069","article-title":"Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug","volume":"26","author":"Meijer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1053\/j.ajkd.2013.10.011_bib57","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1046\/j.1523-1755.2002.00320.x","article-title":"Renal hemodynamic effects of somatostatin are not related to inhibition of endogenous insulin release","volume":"61","author":"Schmidt","year":"2002","journal-title":"Kidney Int"},{"issue":"3","key":"10.1053\/j.ajkd.2013.10.011_bib58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1053\/j.ajkd.2013.03.030","article-title":"Tubular secretion of creatinine in autosomal dominant polycystic kidney disease: consequences for cross-sectional and longitudinal performance of kidney function estimating equations","volume":"62","author":"Spithoven","year":"2013","journal-title":"Am J Kidney Dis"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613013917?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638613013917?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T02:16:21Z","timestamp":1759457781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638613013917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":58,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S0272638613013917"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.10.011","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2013.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}